<DOC>
	<DOCNO>NCT02651662</DOCNO>
	<brief_summary>This open-label , multicenter , dose escalation study REGN2810 REGN1979 patient lymphoma Acute Lymphoblastic Leukemia ( ALL ) . The study treatment period 6 12 month , depend individual patient respond treatment . The follow-up period 6 month patient .</brief_summary>
	<brief_title>Study REGN2810 REGN1979 Patients With Lymphoma Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Key Inclusion Criteria Lymphoma [ ( NonHodgkin Lymphoma ( NHL ) Hodgkin Lymphoma ( HL ) ] : 1 . Have document CD20+ Bcell NHL document HL , active disease either responsive relapse prior therapy , standard care option exist . 2 . Must least 1 bidimensionally measurable lesion ( ≥1.5 cm ) document diagnostic imaging ( CT , PETCT MRI ) . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 4 . Life expectancy least 6 month 5 . Adequate bone marrow function 6 . Adequate organ function 7 . Willing able comply clinic visit studyrelated procedure 8 . Provide sign informed consent Key Exclusion Criteria Lymphoma ( NHL HL ) : 1 . Primary central nervous system ( CNS ) lymphoma , know suspect CNS involvement nonprimary CNS NHL 2 . History current relevant CNS pathology 3 . Ongoing recent ( within 2 year ) evidence significant autoimmune disease require treatment systemic immunosuppressive treatment , may suggest risk iAEs 4 . Prior allogeneic stem cell transplantation 5 . Prior treatment agent block program death1/ program deathligand 1 ( PD1/PDL1 pathway ) , unless benefit demonstrate 6 . Infection human immunodeficiency virus ( HIV ) and/or chronic/active infection hepatitis B virus hepatitis C virus 7 . History hypersensitivity compound tetracycline antibiotic group 8 . Known hypersensitivity allopurinol rasburicase 9 . Pregnant breastfeed woman 10 . Continued sexual activity men woman childbearing potential unwilling practice adequate contraception study Key Inclusion Criteria Acute Lymphoblastic Leukemia ( ALL ) : 1 . Have document CD20+ Blineage ALL least induction 1 cycle consolidation chemotherapy 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 3 . Adequate bone marrow function 4 . Adequate organ function 5 . Willing able comply clinic visit studyrelated procedure 6 . Provide sign informed consent Key Exclusion Criteria ALL : 1 . History current central nervous system ( CNS ) pathology 2 . Burkitt 's leukemia 3 . Prior allogeneic stem cell transplantation le 3 month treatment 4 . Concurrent active malignancy patient receive treatment 5 . Infection human immunodeficiency virus ( HIV ) and/or chronic/active infection hepatitis B virus hepatitis C virus 6 . History hypersensitivity compound tetracycline antibiotic group 7 . Known hypersensitivity allopurinol rasburicase 8 . Pregnant breastfeed woman 9 . Continued sexual activity men woman childbearing potential unwilling practice adequate contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>